According to MHT, BioAnalytix LLC, a spinout from the the Barnett Institute of Chemical and Biological Analysis, has raised seed funding of $858,000 from 11 investors, according to a federal filing.

The firm analyzes and characterizes large-molecule biologic drugs and biosimilars. Kirtland Poss, co-founder and CEO of BioAnalytix, stated that the company was founded in recent months by himself and three others: Robert Garnick, a consultant who runs Lone Mountain Biotechnology and Medical Devices Inc. in Las Vegas; Barry Karger, director of the Barnett Institute; and Billy Wu, senior analytical scientist at Barnett and formerly of Genentech.